Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients

Conditions: Type 2 Diabetes Mellitus Interventions: Drug: SGLT2 inhibitor Sponsors: Jeil Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials